These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology
Application based on results from the TROPION-Breast01 Phase III trial
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
The facility will manufacture tablets, capsules, and injections for the oncology segment
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Subscribe To Our Newsletter & Stay Updated
